Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
Holding ICCM?
Track your performance easily
ICCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.48 - $1.57
Previous Close$0.6
Volume1.66M
Average Volume (3M)620.53K
Market Cap
$29.63M
Enterprise Value$18.80M
Total Cash (Recent Filing)$11.43M
Total Debt (Recent Filing)$599.00K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 26, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding49,520,000
10 Day Avg. Volume1,344,218
30 Day Avg. Volume620,528
Standard Deviation1.03
R-Squared0.02
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)2.41
Price to Sales (P/S)9.35
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.44
Enterprise Value/Gross Profit14.46
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$2.75Price Target Upside286.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Icecure Medical News
PremiumCompany Announcements
IceCure Medical’s ProSense® Gains FDA Panel Support
PremiumCompany Announcements
IceCure Medical Expands Patent Portfolio with New US Approval
PremiumCompany Announcements
IceCure’s ProSense Excels in Global Cryoablation Studies
PremiumCompany Announcements
IceCure Medical’s ProSense® Shows Promising Trial ResultsBulls Say, Bears Say
Bulls Say
Financial PerformancePreliminary revenue for the nine months ended September 30, 2024, was up approximately 98% year-over-year, showing significant growth.
Product ValidationIceCure received marketing authorization from the FDA for the next-generation XSense single probe cryoablation system, which further validates the company’s cryoablation platform technology and should help strengthen market penetration.
Regulatory ApprovalThe FDA Medical Device Advisory Committee Panel gave a favorable recommendation for ICCM's ProSense System for the treatment of early-stage low-risk invasive breast cancer, indicating a high likelihood of approval.
Bears Say
Clinical TrialsCryoablation systems face the risk of failure in clinical trials, which could impact their future viability.
Commercial SuccessCryoablation systems may struggle to achieve commercial success due to factors like market size, penetration rate, or competition.
Regulatory ApprovalThere is a risk that cryoablation systems may not secure regulatory approval in the U.S. and globally.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.08% Other Institutional Investors
99.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ICCM FAQ
What was IceCure Medical’s price range in the past 12 months?
IceCure Medical lowest stock price was $0.48 and its highest was $1.57 in the past 12 months.
What is IceCure Medical’s market cap?
Currently, no data Available
When is IceCure Medical’s upcoming earnings report date?
IceCure Medical’s upcoming earnings report date is Nov 26, 2024 which is in 3 days.
How were IceCure Medical’s earnings last quarter?
IceCure Medical released its earnings results on Aug 20, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.01.
Is IceCure Medical overvalued?
According to Wall Street analysts IceCure Medical’s price is currently Undervalued.
Does IceCure Medical pay dividends?
IceCure Medical does not currently pay dividends.
What is IceCure Medical’s EPS estimate?
IceCure Medical’s EPS estimate is -$0.08.
How many shares outstanding does IceCure Medical have?
IceCure Medical has 49,517,660 shares outstanding.
What happened to IceCure Medical’s price movement after its last earnings report?
IceCure Medical reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 17.187%.
Which hedge fund is a major shareholder of IceCure Medical?
Among the largest hedge funds holding IceCure Medical’s share is ARK Investment Management LLC. It holds IceCure Medical’s shares valued at N/A.
---
Icecure Medical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (286.13% Upside)
$2.75 (286.13% Upside)
Blogger Sentiment
Bullish
ICCM Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
-94.22%
Trailing 12-Months
Asset Growth
-32.32%
Trailing 12-Months
Company Description
IceCure Medical
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women's health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
---
ICCM Earnings Call
Q2 2024
0:00 / 0:00
---
ICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(286.13% Upside)
Technical Analysis
Best Analysts Covering ICCM
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-20.77%
reiterated a buy rating 15 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -20.77% per trade.
---